How to Buy Biomarin Pharmaceutical Stock
Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions.
Biomarin Pharmaceutical stock last closed at $63.94, down 1.75% from the previous day, and has increased 15.96% in one year. It has overperformed other stocks in the Biotechnology industry by 0.38 percentage points. Biomarin Pharmaceutical stock is currently +29.8% from its 52-week low of $49.26, and -9.92% from its 52-week high of $70.98.
At the moment, there are 193.57M shares of BMRN outstanding. The market value of BMRN is $12.38B. In the last 24 hours, 4.46M BMRN shares were traded.
How to Buy Biomarin Pharmaceutical Stock
Not sure how to invest in Biomarin Pharmaceutical stock? Here's how.
- Choose where to buy Biomarin Pharmaceutical stock: You need to pick an online brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you determine where to buy Biomarin Pharmaceutical stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Put funds into your investment account: Select your payment method and add your details.
- Research Biomarin Pharmaceutical stock: The Biomarin Pharmaceutical ticker symbol is BMRN. Is Biomarin Pharmaceutical stock a good investment? Should you buy shares of BMRN? How do BMRN's underlying business fundamentals look? Do top analysts think Biomarin Pharmaceutical is a good buy? Why has BMRN's stock price moved recently? (Hint: Our stock research tools can help you decide if BMRN is a good stock to buy).
- Make your BMRN buy order: Decide if you will purchase BMRN shares at the current market price or use a limit order to buy BMRN shares at a given price.
- Get notifications regarding your BMRN investment: Create a watchlist to important notifications about your new investment in Biomarin Pharmaceutical shares.
Step 1: Choose where to buy Biomarin Pharmaceutical stock
You need an online brokerage account in order to access the NASDAQ market and buy BMRN stock.
Our recommended brokerage: eToro
We believe that eToro is the best stock brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global markets: From Technology to Healthcare, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected your brokerage, you'll need to fill out some personal info so you are able to buy BMRN stock today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to open a new brokerage account.
- Send your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've created your account on apps for stock market, your next step is to transfer the money for your investment:
Check out the walkthrough below if you need help transferring money into your investment account.
Step 4: Research Biomarin Pharmaceutical stock
Once you have decided on the best place to buy Biomarin Pharmaceutical stock, it's absolutely critical to research their stock prior to investing, so you actually understand the risk as well as the upside.
Biomarin Pharmaceutical Metrics
Biomarin Pharmaceutical Fundamentals
WallStreetZen was built to help part-time investors perform more accurate fundamental analysis quickly.
You can view all of the due diligence checks on BMRN's stock page.
Is BMRN stock undervalued or overvalued?
You can use many financial metrics, analyses, models, and charts to gauge BMRN's intrinsic value.
Using relative valuations ratios:
- BMRN may be overvalued based on its P/E ratio of 168.26x, relative to Biotechnology industry P/E ratio of 9.29x
- BMRN could be undervalued based on its P/B ratio of 1.96x, relative to Biotechnology industry P/B ratio of 5.28x
- BMRN could be overvalued based on its PEG ratio of 1.11x
You can do additional valuation research on BMRN's stock here.
How do BMRN Financials look?
Pros:
- There are more short-term assets than long-term liabilities on the BMRN balance sheet.
- BMRN's operating cash flow of $857.09M allows it to safely service it's debt of $4.19B.
- There are more short-term assets than short-term liabilities on the BMRN balance sheet.
Cons:
- BMRN earnings of $232.72M is not enough to cover its interest payments.
- BMRN has a relatively high debt to equity ratio of 0.85.
- BMRN profit margin has gone down from 21.5% to 2.1% in the past year.
- Total BMRN debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy Biomarin Pharmaceutical stock, according to analysts?
Out of 14 Equities analysts who give recommendations on BMRN, the consensus analyst rating on BMRN is a Strong Buy
It's important to keep in mind that analyst forecasts are not recommendations, nor are they financial advice.
Latest BMRN Analyst Upgrades/Downgrades
Whitney Ijem, a top 6% analyst from Canaccord Genuity maintains BMRN with a strong buy rating and raises their BMRN price target from $111.00 to $114.00, on Aug 10, 2026.
Canaccord Genuity's Whitney Ijem raised their price target on Biomarin Pharmaceutical (NASDAQ: BMRN) by 2.7% from $111 to $114 on 2026/08/10. The analyst maintained their Strong Buy rating on the stock.
BioMarin Pharmaceutical reported its Q2 2026 earnings.
Raising their estimates and price target, Ijem cited the quarter's results and management's FY 2026 guidance raises for:
- Total revenue.
- Voxzogo revenue.
- EPS.
Earnings Report
For Q2 2026, Biomarin Pharmaceutical reported:
- EPS of $1.20, which beat the Zacks Consensus Estimate of $0.96 but missed Q2 2025's $1.44.
- Revenue of $989.7M, which beat the Zacks Consensus Estimate of $922M and was up 20% Y/Y.
For FY 2026, management guided:
- EPS of $4.90 to $5.10, up from the prior $4.85 to $5.05.
- Revenue of $3.875B to 3.925B, up from the prior $3.825B to $3.925B.
President & CEO Alexander Hardy commented: "This quarter, we executed strongly across our portfolio while rapidly integrating Amicus into BioMarin's operations and advancing plans to accelerate growth for GALAFOLD and POMBILITI + OPFOLDA, and extending the benefit of these medicines to more patients worldwide.
"Strong global demand led us to increase full-year VOXZOGO revenue guidance to at least $1 billion in 2026.
"{Adding to this momentum is the opportunity to advance our second potential indication with VOXZOGO, hypochondroplasia, based on recent pivotal data that exceeded our expectations.
"With our larger, more diversified commercial portfolio of innovative medicines, we are positioned to deliver additional growth and increased profitability.
"We expect strong execution through the remainder of 2026, bringing together our expanded portfolio, scale and disciplined integration efforts to reach more patients living with serious genetic conditions around the world."
Matthew Harrison, a top 20% analyst from Morgan Stanley maintains BMRN with a strong buy rating and raises their BMRN price target from $119.00 to $124.00, on Aug 7, 2026.
Leland Gershell, a top 4% analyst from Oppenheimer maintains BMRN with a buy rating and raises their BMRN price target from $95.00 to $97.00, on Aug 7, 2026.
Eric Joseph, a bottom 9% analyst from Citigroup maintains BMRN with a strong buy rating and raises their BMRN price target from $75.00 to $76.00, on Jul 16, 2026.
Luca Issi, a top 12% analyst from RBC Capital maintains BMRN with a hold rating and lowers their BMRN price target from $66.00 to $62.00, on Jul 7, 2026.
You can dive deeper into what analysts are saying on the Biomarin Pharmaceutical stock forecast page.
BMRN Technicals
Is BMRN Making Money?
Last year, BMRN earnings were $72.97M. Over the past 5 year, BMRN's earnings have gone up by -39.24% per year. This was slower than the Biotechnology industry average of 9.9%.
Last year, BMRN revenue was $3.41B. In the past five year, BMRN's revenue has gone up by 12.19% per year. This was slower than the Biotechnology industry average of 24.78%.
You can analyze BMRN's earnings and revenue performance here.
Latest Insiders Trades at BMRN
In the past 12 months, executives and large shareholders at BMRN have sold more shares than they have bought.
George Eric Davis, CLO;EVP of BMRN, was the latest BMRN insider to sell. They sold $1,163,748.19 worth of BMRN stock on Sep 2, 2026.
Dig into more about who owns BMRN shares here.
Can I get consistent income from BMRN stock?
No, Biomarin Pharmaceutical doesn't provide an income stream by paying out dividends.
What do other investors have to say about BMRN?
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your BMRN buy order
There are two primary order types:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are mostly fine for most investors. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a given price, place a limit order.
Click the Open Trade button and your broker will place your order.
If you need additional help with buying stocks on eToro, click the helpful video below:
Step 6: Get notifications regarding your BMRN investment
Now that you own some BMRN shares, you'll want to keep up with your new investment.
Start a watchlist to track your BMRN stock.
BMRN Feed
How to Buy Stock in Biomarin Pharmaceutical
To summarize, here are the 6 steps to buy Biomarin Pharmaceutical stock:
- Choose where to buy Biomarin Pharmaceutical stock
- Open your brokerage account
- Put funds into your investment account
- Research Biomarin Pharmaceutical stock
- Make your BMRN buy order
- Get notifications regarding your BMRN investment
If you are looking for a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to watch your new investment in Biomarin Pharmaceutical, create a watchlist on WallStreetZen today.
Other Articles You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.